文献速递乳腺癌放疗姑息放疗与转移瘤

局部晚期乳腺癌患者接受根治性放疗联合淋巴结推量照射

Definitive Radiation With Nodal Boost for Patients With Locally Advanced Breast Cancer.
PubMed 文献 · Pract Radiat Oncol · 2022-11-23

本回顾性研究纳入79例晚期淋巴结病变乳腺癌患者,接受辅助放疗并对锁骨上、内乳和/或腋窝淋巴结推量照射。中位随访30个月,3年局部无复发生存率94.5%、无病生存率86.3%、总生存率93.8%。失败多为远处转移,无孤立局部复发;内乳+腋窝/锁骨上组失败率最高(41.7%)。

要点

  • 79例晚期淋巴结病变乳腺癌患者接受辅助放疗联合淋巴结推量照射,中位随访30个月。
  • 3年局部无复发生存率94.5%、无病生存率86.3%、总生存率93.8%。
  • 失败率内乳+腋窝/锁骨上组41.7%,内乳组5.4%,腋窝/锁骨上组13.3%。

核心结论

  • 在该局部晚期乳腺癌人群中,多数失败为远处转移,无孤立局部复发。
  • 内乳+腋窝/锁骨上组失败率最高(约40%),这些患者需要进一步治疗升级。

研究设计与样本

  • 回顾性研究纳入79例晚期淋巴结病变乳腺癌患者,接受辅助放疗并对锁骨上、内乳和/或腋窝淋巴结推量照射。
  • 所有患者系统治疗后影像学改变提示大体淋巴结病变。

主要发现

  • 中位随访30个月,3年局部无复发生存率94.5%、无病生存率86.3%、总生存率93.8%。
  • 粗失败率13.9%(10.1%单纯远处失败;3.8%远处失败+局部区域失败)。
  • 按推量组失败率:腋窝/锁骨上组13.3%(10.0%单纯远处失败;3.3%远处失败+局部区域失败),内乳组5.4%(2.7%单纯远处失败,2.7%远处失败+局部区域失败),内乳+腋窝/锁骨上组41.7%(33.3%远处失败,8.3%远处失败+局部区域失败)。
  • 无远处失败时无局部区域失败;中位失败时间22.8个月(四分位距18-34个月)。
  • 临床肿瘤大小与更差无病生存相关(HR 9.78;95%CI 2.07-46.2;P=0.004),内乳+腋窝/锁骨上 vs 内乳或腋窝/锁骨上单独与更差无病生存相关(HR 9.49;95%CI 2.67-33.7;P=0.001);多因素分析中内乳+腋窝/锁骨上 vs 内乳或腋窝/锁骨上单独保留显著性(HR 4.80;95%CI 1.27-18.13;P=0.02)。

关键数值与推荐

  • 所有患者乳腺/胸壁和区域淋巴结初始接受50 Gy。
  • 46.8%接受内乳推量,38.0%接受腋窝/锁骨上推量,15.2%接受内乳+腋窝/锁骨上推量。
  • 中位淋巴结推量剂量10 Gy(范围10-20 Gy),其中内乳21.6%、腋窝/锁骨上16.7%、内乳+腋窝/锁骨上16.7%接受14-20 Gy。
  • 激素受体阳性74.7%,人表皮生长因子受体2阴性83.5%;临床N2期12.7%、cN3A期21.5%、cN3B期51.9%、cN3C期5.1%;97.5%接受化疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal local therapy of patients with nodal disease in supraclavicular (SCV), internal mammary nodes (IMN) and level III axilla is not well studied. We aimed to evaluate the outcomes of patients with breast cancer and advanced nodal disease that received a nodal boost. METHODS AND MATERIALS: This retrospective study included 79 patients with advanced nodal disease who underwent adjuvant radiation with a nodal boost to the SCV, IMNs, and/or axilla. All patients had radiographic changes after systemic therapy concerning for gross nodal disease. Overall survival, disease-free survival (DFS), and local recurrence-free survival were estimated using the Kaplan-Meier method. RESULTS: All patients received an initial 50 Gy to the breast/chest wall and regional nodes, of whom 46.8% received an IMN boost, 38.0% axillary (ax)/SCV boost, and 15.2% both IMN and ax/SCV boost (IMN + ax/SCV). Most patients had hormone receptor positive (74.7%) and human epidermal growth factor receptor 2 negative disease (83.5%). In addition, 12.7% of patients had clinical (c) N2 disease, 21.5% cN3A disease, 51.9% cN3B disease, and 5.1% cN3C disease. Most patients received chemotherapy (97.5%). The median nodal boost dose was 10 Gy (range, 10-20 Gy), with 21.6% of IMN, 16.7% of ax/SCV, and 16.7% of IMN + ax/SCV receiving 14 to 20 Gy. With a median follow up of 30 months, the 3-year local recurrence-free survival, DFS, and overall survival rates were 94.5%, 86.3%, and 93.8%, respectively. Crude rates of failure were 13.9% (10.1% distant failure [DF] alone; 3.8% DF + locoregional failure [LRF]). Rates of failure by boost group were 13.3% for ax/SCV (10.0% DF alone; 3.3% DF + LRF), 5.4% for IMN (2.7% DF alone, 2.7% DF + LRF), and 41.7% for IMN + ax/SCV (33.3% DF, 8.3% DF + LRF). There were no LRFs without DFs. The median time to failure was 22.8 months (interquartile range, 18-34 months). Clinical tumor size and IMN + ax/SCV versus IMN or ax/SCV alone was associated with worse DFS (hazard ratio [HR]: 9.78; 95% confidence interval [CI], 2.07-46.2; P = .004 and HR: 9.49; 95% CI, 2.67-33.7; P = .001, respectively). On multivariate analysis, IMN + ax/SCV versus IMN or ax/SCV alone retained significance (HR: 4.80; 95% CI, 1.27-18.13; P = .02). CONCLUSIONS: In this population of patients with locally advanced breast cancer, the majority of failures were distant with no isolated LRFs. Failures were the highest in the IMN + ax/SCV group (∼40%). Further treatment escalation is necessary for these patients.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Purswani JM, Oh C, Teruel JR, et al. Definitive Radiation With Nodal Boost for Patients With Locally Advanced Breast Cancer. Pract Radiat Oncol. 2022. PMID: 36435389. doi:10.1016/j.prro.2022.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。